CIRC(01763) successfully obtained a radiation safety license for the second phase of the development and production base of radiation sources. The largest radiation source research and development production base in Asia has been fully completed and put into operation.

CIRC(01763) announces that recently, the radiation source R&D production base project (Phase 2) of Chengdu Zhongke Gao Tong Isotope Co., Ltd., a subsidiary of CIRC, has been completed and successfully obtained an additional approval for the radiation safety license. The production lines for californium-252, cesium-137, americium-241, and other radiation sources have officially started production, fully meeting the diverse market demands. In August 2025, Phase 1 of the radiation source R&D production base project obtained a radiation safety license. The approval of Phase 2 marks the completion of Asia's largest radiation source R&D production base, with 14 production lines for sources such as carbon-14 and krypton-85, capable of producing over 70 high-quality radiation source products. The annual production scale of radiation sources will exceed 100,000 pieces, meeting the demands in various fields such as industry, agriculture, medicine, national defense, and aerospace in China. The full operation of this project signifies that China is accelerating technological upgrades and transforming old and new capacities in the sealed radiation source field, consolidating its leading position in the R&D and industrial application of radiation sources. With the release of production capacity, the related products will not only meet domestic demand but also continue to expand into international markets, actively serving countries along the "Belt and Road" initiative.